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Sporadic inclusion body myositis (s-IBM) is characterized histo-
logically by the association of concomitant inflammatory and de-
generative processes. We evaluated the sensitivity and specificity 
of different markers of the degenerative process in order to refine 
the histological diagnosis. We performed an immunohistochemi-
cal study with antibodies directed against ubiquitin, amyloid-β 
precursor  protein  (AβPP),  amyloid-β  (Aβ), SMI-31, SMI-310, 
Tar-DNA binding protein-43 (TDP-43) and p62 on s-IBM and 
control muscle biopsies. Based on conventional stains 36 patients 
with characteristic clinical features of s-IBM were subclassified as 
presumed definite s-IBM (d s-IBM, n = 17) or possible s-IBM (p 
s-IBM, n = 19) according to the presence or absence of vacuolated 
muscle fibers. Immunohistochemically, TDP-43 and p62 were the 
most sensitive markers, accumulating in all d s-IBM and in 31% 
and 37%, respectively, of the p s-IBM cases and thus enabling 
reclassification of these cases as d s-IBM. We recommend using 
TDP-43 and p62 antibodies in the histological diagnosis workup 
of s-IBM. The specificity of these markers has to be further vali-
dated in prospective series.
Key words: inclusion body myositis, inflammatory myopathy, pro-
tein aggregate myopathy, immunohistochemistry, Tar-DNA binding 
protein-43, p62
Introduction
Sporadic  inclusion  body  myositis  (s-IBM)  is  the 
most common acquired inflammatory myopathy in pa-
tients over the age of 50 years (1). It is characterized by 
slowly  progressive,  asymmetric  atrophy  and  weakness 
of both proximal and distal muscles, predominantly af-
fecting the finger and wrist flexors and quadriceps (1). 
Pathological  features  include  two  processes  occurring 
in parallel: one degenerative and one inflammatory. The 
degenerative  process  results  in  atrophic  muscle  fibers, 
vacuolar degeneration and accumulation of multiple pro-
teins in vacuolated or non-vacuolated muscle fibers in-
cluding ubiquitin, amyloid-β precursor protein (AβPP), 
amyloid-β  (Aβ),  phosphorylated-tau  (p-tau)  and  many 
other proteins (2). These protein aggregates form multi-
ple or single foci of amyloid, due to their β-pleated-sheet 
configuration, present in 60 to 80% of the s-IBM vacu-
olated muscle fibers, within vacuoles or mostly in the 
non-vacuolated cytoplasm (3). Phosphorylated tau is vis-
ible ultrastructurally as 15-21 nm-diameter paired-helical 
filaments (PHF) or tubulofilaments and is present in the 
cytoplasm of vacuolated fibers or rarely in the nuclei (3). 
The inflammatory process is characterized by endomy-
sial infiltrates of mononuclear cells with CD8+ cytotoxic 
T-lymphocytes invading major histocompatibility class I-
expressing non-necrotic muscle fibers (4). 
According  to  Griggs’  criteria  (1995),  both  proc-
esses are mandatory for a diagnosis of definite s-IBM (d 
s-IBM). Furthermore, biopsy must show either amyloid 
deposits evidenced by a fluorescent method or tubulo-
filaments by electron microscopy. Both methods are not 
performed routinely everywhere and their sensitivity has 
never been evaluated. If inflammation only is present, the 
pathological diagnosis of possible s-IBM (p s-IBM) is 
made. The alternative diagnosis is that case is polymy-
ositis. Differentiating both is important since polymyosi-
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tis usually responds to corticosteroids and conventional 
immunosuppressive  treatments,  whereas  s-IBM  does 
not (5). However, in clinical practice, there is clear evi-
dence that some patients have clinical features of s-IBM, 
although muscle samples lack the canonical features of s-
IBM, even on repeated biopsies (6). This can be attributed 
either to the patchy distribution or to the late appearance 
of degenerative features in some patients. In the era of the 
search for effective treatments of this chronic, progressive 
and disabling disorder, there is a need for easy and reli-
able methods to refine the diagnosis of s-IBM (7). 
The purpose of this study was to evaluate and com-
pare the sensitivity and specificity of different markers of 
degeneration accumulated in s-IBM muscles in order to 
determine if some of them can be recommended in the 
histological diagnosis workup. 
Patients and methods
Patients
Skeletal muscle from 36 patients with s-IBM (19 fe-
males, 17 males), were obtained for diagnostic purposes 
after informed consent at the Reference Center for Neu-
romuscular Diseases at the Institut de Myologie, Hopital 
Pitié-Salpêtrière. The assessment of amyloid deposits (by 
fluorescence-enhanced Congo-red or crystal violet staining) 
and phosphorylated-tau (by electron microscopy as PHF) 
on muscle biopsies was not so far routinely performed, 
not permitting to fulfill a priori all Griggs’ criteria for d 
s-IBM.  Nevertheless,  all  patients  presented  clinical  and 
electrophysiological features characteristic of s-IBM (1). 
On pathological analysis, we distinguished two groups of 
s-IBM for comparison. We called the first presumed defi-
nite s-IBM (d s-IBM, n = 17, 8 females, 9 males) and the 
second possible s-IBM (p s-IBM, n = 19, 12 females, 7 
males). Presumed d s-IBM was defined by the presence 
of inflammation including invasion of nonnecrotic fibers 
by mononuclear cells, and vacuoles (rimmed or not). Pos-
sible s-IBM was defined by the presence of inflammation 
with or without invaded fibers but no or single vacuole. 
Two patients had two biopsies, performed at 2 and 4 years 
of interval, the first classified as p s-IBM and the second 
as presumed d s-IBM. Muscles from patients with poly-
myositis or dermatomyositis (PM/DM, n = 7), muscular 
dystrophies (MD, n = 8, including 3 dysferlinopathies, 3 
calpainopathies, 1 Bethlem myopathy, 2 unspecified limb 
girdle muscular dystrophies) and normal muscle biopsies 
from individuals who underwent diagnostic procedures for 
myalgia and fatigue (N, n = 6) served as controls. Age at 
biopsy was similar between patients with presumed d s-
IBM, p s-IBM and controls. It was significantly younger 
for patients with PM/DM and MD (data not shown). The 
study was approved by the local ethics committees of the 
Pitié-Salpêtrière Hospital, Paris, France. Age at biopsy and 
disease duration did not differ between male and female 
patients (data not shown). 
Methods
Skeletal muscle biopsies were classified as presumed 
d s-IBM and p s-IBM according to the abnormalities ob-
served  on  conventional  stains  (haematoxilin-eosin  and 
Gomori  trichrome).  Immunohistochemistry  was  per-
formed on 8 μm thick cryosections, which were air-dried 
and fixed either in 4% formaldehyde for Aβ at room tem-
perature or in cold acetone at –20°C (for all other primary 
antibodies) for 10 minutes each. After washing in phos-
phate buffered saline (PBS) the sections were incubated 
with 10% normal goat serum (G9023; Sigma) in antibody 
diluent (S3022; Dako) for 30 minutes to minimize unspe-
cific binding. Primary antibodies (all mouse monoclonal; 
except against TDP-43 and p62: rabbit polyclonal) were 
directed against phosphorylated neurofilament (SMI-31; 
1:1000 and SMI-310; 1:1000, Covance), Aβ (β-A4; 1:50; 
Dako), ubiquitin (1:1000; Dako), AβPP (1:1000, Milli-
pore), TDP-43 (1:2000; Proteintech Group), p62 (1:100; 
Santa Cruz Biotech). Stainings for Aβ were performed 
manually with an incubation of the primary antibodies 
overnight at 4°C. Other stains were done with an auto-
mated  slide  staining  system  (BenchMark  XT, Ventana 
medical systems). Binding of the primary antibodies was 
detected with a peroxidase reaction and visualized with 
3,3’-diaminobenzidine as chromogen (Dako Real™ De-
tection System (K5001; Dako) for manual stains; second-
ary reagents from Ventana medical systems for automated 
stains). The  primary  antibody  was  omitted  for  control 
purposes, and IgG1 isotype controls were included in the 
protocol. The percentages of fibers containing cytoplas-
mic deposits were determined on serial sections by count-
ing 200 fibers in 20 random fields with a 40x objective. 
Results
Percentage of cases with immunoreactive fibers
In order to investigate which marker would turn out 
most useful for diagnostic purposes, we calculated the 
percentage of cases with immunoreactive fibers in each 
category of muscles biopsies (Table 1). None of the nor-
mal muscle controls had immunoreactive fibers for the 
different markers tested. p62 and TDP-43 immunoreac-
tive fibers were observed in all presumed d s-IBM cases 
and in 37 and 31% of p s-IBM, respectively. That means 
that: 1) a posteriori all d s-IBM patients were well classi-
fied and finally, by the presence of PHF evidenced by p62 
(Nogalska et al., 2009) fulfill all the Griggs criteria for d Markers of degeneration in inclusion body myositis
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s-IBM. The percentage was increased to 42% by adding 
the cases of p s-IBM re-classified with each marker. TDP-
43 deposits were not observed in any of the pathological 
controls. p62 deposits were observed in one case of poly-
myositis. SMI-31 and ubiquitin aggregates were present 
in 93% and 87% of presumed d s-IBM, and in 15% and 
31% of p s-IBM, respectively. Ubiquitin aggregates were 
as frequent in p s-IBM as TDP-43 aggregates but also ob-
served in 28.5% of PM/DM muscles and 12.5% of MD 
muscles. SMI31 aggregates were observed in 12.5% of 
MD muscles. The other markers were present in 13% of 
presumed d s-IBM but in none with p s-IBM. 
Percentage of immunoreactive fibers per cases
Table 2 shows the percentage of immunoreactive fib-
ers per cases. The percentage of immunoreactive fibers was 
similar for TDP-43 and p62 in presumed d s-IBM and p 
s-IBM. Immunoreactivity was present either as small mul-
tiple granular aggregates in the sarcoplasm of non-vacu-
olated fibers or larger rounded deposits in the vacuole of 
the vacuolated fibers. In vacuolated fibers, they could be 
associated with small multiple granular aggregates in the 
non-vacuolated cytoplasm (Fig. 1). In cases diagnosed as 
p s-IBM, both markers permitted to detect immunoreactive 
fibers with the same characteristics as those described be-
fore, thus permitting to re-classify some biopsies initially 
classified with the routine staining as p s-IBM in presumed 
d s-IBM. The percentage of immunoreactive fibers per bi-
opsy was much less frequent for the other markers.
Discussion
Sporadic inclusion body myositis is a unique disorder 
among inflammatory myopathies, characterized patholog-
ically by the presence of mononuclear cell inflammation 
associated with degenerative features including atrophy 
Table 1. Percentage of cases with immunoreactive fibers. 1: one polymyositis, 2: one Bethlem myopathy, 3: one poly-
myositis and one dermatomyositis, 4: one dysferlinopathy.
d s-IBM
(n = 17)
p s-IBM
(n = 19)
PM/DM
(n = 7)
Dystrophies
(n = 8)
N
(n = 6)
p62 100% 37% 14%1 0% 0%
TDP43 100% 31% 0% 0% 0%
SMI 31 93% 15% 0% 12.5%2 0%
Ubiquitin 87% 31% 28.5%3 12.5%4 0%
Aβ 13% 0% 0% 0% 0%
APP 13% 0% 0% 0% 0%
SMI 310 13% 0% 0% 0% 0%
Table 2. Percentage of immunoreactive fibers per biopsy for each marker.
d s-IBM
(n = 17)
p s-IBM
(n = 19)
PM/DM
(n = 7)
MD
(n = 8)
N
(n = 6)
p62 12.1 ± 6.5
(1.5-28)
1.9 ± 2.8
(0-8)
1.6 ± 4.1
(0-11)
0 0
TDP43 11.6 ± 11.2
(0.5-47.5)
2.1 ± 3.8
(0-13.8)
0 0 0
SMI 31 3.4 ± 2.5
(0-6.5)
0.05 ± 0.9
(0 – 0.5)
0 0.06 ± 0.2
(0 – 0.5)
0
Ubiquitin 1.1 ± 1.2
(0 – 3.5)
0.1 ± 0.3
(0 – 1)
0.1 ± 0.2
(0 – 0.5)
0.06 ± 0.2
(0 – 0.5)
0
Beta A4 0.1 ± 0.2
(0 – 1)
0 0 0 0
APP 0.1 ± 0.2
(0 – 1)
0 0 0 0
SMI 310 0.1 ± 0.2
(0 – 1)
0 0 0 0O. Dubourg et al.
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of muscle fibers, vacuolar degeneration and accumulation 
of multiple proteins (2). Some of the proteins accumu-
lated in vacuolated muscle fibers in s-IBM are also found 
abnormally accumulated in the brain in Alzheimer dis-
ease (AD), suggesting that both diseases could have some 
common pathogenic mechanisms. These proteins include 
ubiquitin, amyloid-β (Aβ), amyloid-β precursor protein 
(AβPP),  phosphorylated-tau  (p-tau),  apolipoprotein  E 
(ApoE) and α1-antichymotrypsin (8-13). It has also been 
shown that α-synuclein, cellular prion protein as well as 
markers of oxidative stress, proteins of the ubiquitine-
proteasome system, endoplasmic reticulum chaperones, 
heat shock proteins, signal transduction components are 
accumulated in s-IBM muscle fibers (2). The elimination 
of improperly folded or unfolded proteins is normally en-
sured in the cell by several mechanisms, including refold-
ing through endoplasmic reticulum chaperones and heat 
shock proteins, and degradation by the ubiquitine-protea-
some system and through autophagosomes formation, all 
processes which might be impaired in s-IBM. Predispos-
ing genes and an aging cellular milieu may contribute to 
the dysfunction of these mechanisms, leading to the ac-
cumulation of insoluble proteins aggregates. 
The extensive description of proteins aggregated in 
s-IBM has largely contributed to a better understanding 
of the physiopathology of s-IBM. However, it has not 
contributed in the same way to the improvement of histo-
logical diagnosis. As a matter of fact, difficulties for de-
fining s-IBM by its canonical biopsy features have been 
stressed by several authors (6, 7). Distinguishing between 
s-IBM and polymyositis is though of great importance. 
On one hand, it has been shown from the follow-up of 
two large cohorts of patients with s-IBM that immuno-
suppressive treatments seem not to ameliorate the natural 
course and even so might hasten progression of the dis-
ease (14). Therefore, it will be crucial to include patients 
Figure 1. Immunohistochemistry on frozen sections with TDP-43 (A, B) and p62 (C, D) antibodies. TDP-43 and p62 
immunoreactivity was present as larger rounded deposits in the vacuole of the vacuolated fibers (A, C, arrow) and/
or as small multiple granular aggregates in the non-vacuolated cytoplasm of vacuolated fibers (B, arrowhead) or non-
vacuolated fibers (D, arrowhead). Markers of degeneration in inclusion body myositis
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with the right diagnosis in future clinical trials aimed at 
demonstrating  the  efficacy  of  treatments.  Considering 
the canonical features mandating for a definite diagnosis 
in Griggs’ criteria, it has been shown that amyloid de-
posits evidenced by red fluorescence are rarely encoun-
tered (15, 16) and electron microscopy to detect 15-21 
nm tubulofilaments is not performed routinely. In the past 
few years, efforts have been made to identify markers of 
the degenerative process which might be used for diagno-
sis purposes. These markers are SMI-31, SMI-310, p62 
and  TDP-43.  SMI-31,  reacting  with  a  phosphorylated 
epitope of neurofilament heavy chain and crossreacting 
with tau, detects tubulofilamentous inclusions. It has been 
demonstrated to be highly specific and proposed to re-
place electron microscopy (3). SMI-31 immunoreactive 
deposits have been identified in 80% of the vacuolated 
muscle fibers, either within the vacuoles or in the vac-
uole-free cytoplasm, and occasionally in non-vacuolated 
fibers (17). This marker was judged to be helpful to dif-
ferentiate,  among  patients  with  biopsies  showing  in-
flammation and rimmed vacuoles, treatment responders 
and non responders (18). Another marker of phosphor-
ylated-tau, SMI-310, was expressed in 60 to 80% of the 
vacuolated muscle fibers in s-IBM, but not in hereditary 
inclusion  body  myopathy  (h-IBM),  an  heterogeneous 
group of inherited disorders characterized histologically 
by vacuolated muscle fibers but no inflammation (17). 
p62, also known as sequestosome 1, is a shuttle protein 
transporting polyubiquinated proteins for their degrada-
tion by both the proteasome and lysosome. This protein 
is a component of the inclusions in several neurodegen-
erative disorders, including AD (19). Given the similari-
ties between s-IBM and AD, p62 was studied on s-IBM 
muscles and shown to be present as linear, squiggly or 
small rounded aggregates in all specimens, permitting to 
distinguish between s-IBM and polymyositis (20). Intra-
cellular protein aggregation has been identified in other 
muscle  disorders  grouped  under  the  term  of  “protein 
aggregate myopathies” (PAM) (21). PAM includes dif-
ferent types of genetic myopathies such as myofibrillar 
myopathies (MFMs), hereditary inclusion body myopa-
thies  (h-IBM),  actinopathies  and  myosinopathies  (22). 
The literature upon PAM has shed light on other proteins 
that could be involved in the physiopathology of s-IBM. 
In particular, it has been show that DNA-binding protein 
43 (TDP-43) is accumulated in desminopathies and myo-
tilinopathies, subgroups of MFMs caused by mutations 
in DES and MYOT genes (21), h-IBM with Paget’s dis-
ease of the bone and fronto-temporal dementia (23), due 
to valosin containing protein (VCP) gene mutations and 
s-IBM (16, 21, 24). TDP-43 is a 414-amino acid nuclear 
protein, highly conserved and widely expressed in several 
tissues, implicated in exon skipping, transcription regula-
tion, and other biologic processes through its binding to 
DNA, RNA, and/or proteins (25). TDP-43 is one compo-
nent of the ubiquinated inclusions in the brain of patients 
with frontotemporal dementias and amyotrophic lateral 
sclerosis (26). According to a recent study, sarcoplasmic 
immunoreactivity for TDP-43 is highly sensitive and spe-
cific of s-IBM among inflammatory myopathies (16). 
By our systematic screening, we have demonstrated 
that TDP-43 and p62 were the more sensitive markers for 
the diagnosis of s-IBM. These results confirm those of pre-
vious reports (16, 20). The immunoreactivity appears either 
as rounded aggregates within the vacuole or as small mul-
tiple granular aggregates in the vacuolated-free cytoplasm 
of vacuolated fibers or in non-vacuolated fibers. The origi-
nality of our approach was to compare the results in two 
groups with either presumed d s-IBM or p s-IBM. We used 
the term “presumed” because detection of amyloid depos-
its and/or detection of PHF was not performed routinely, 
and thus, our criteria for d s-IBM did not fulfilled strictly 
Grigg’s criteria. Nevertheless, detection of p62 aggregates 
in all presumed d s-IBM cases confirm a posteriori that 
our diagnosis was valid because p62 has been shown by 
immunoelectronmicroscopy to co-localize with bundles of 
PHF (20). Our study shows that the use of p62 and TDP-
43 permits to re-classify 37% and 31%, respectively, of our 
p s-IBM diagnosed with conventional stain as presumed d 
s-IBM. This percentage was increased to 42% by adding 
the cases re-classified with each marker. This information is 
very useful for the clinician to guide the therapeutic options. 
In our hands, the percentage of immunoreactive fibers in 
presumed d s-IBM and p s-IBM was similar for both mark-
ers. Concerning the specificity, we have shown that TDP-43 
immunoreactivity was observed neither in pathological nor 
in normal control muscle biopsies. TDP-43 positive inclu-
sions were found in 1 of 12 steroid responsive polymyosi-
tis in another study (23). p62 aggregates were identified as 
small diffuse speckles in the cytoplasm of numerous fibers 
in one case of polymyositis (20). The pattern of immuno-
reactivity was quite different than that observed in s-IBM. 
Similar observation has been mentioned in rare fibers in 
polymyositis,  dermatomyositis  and  non-specific  myopa-
thies (20). We suggest that both markers could be used in 
the histological diagnosis workup of s-IBM. The contribu-
tion of these markers to the diagnosis of s-IBM has to be 
further validated in prospective series. 
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